Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)

Postby helios » Sat Mar 13, 2010 12:10 pm

:arrow: A year ago, i was evaluating the PEG technology ...

1. Clinical validation of Nektar's technology platform with small molecules
- Achieved first oral bioaviailability with a polymer conjugated drug
- Demostrated Nektar technology can modulate crossing of the blood-brain barrier
- Showed platform can greatly improve PK profile of anti-cancer agents to enhance efficacy and reduce side effects

2. Groundbreaking agreement signed with AstraZeneca
- Highlights value of Nektar's technology platform
- $1.5 B in milestones with significant double-digit royalities

3. Entered 2010 with $396 M in cash at end-2009
- Net positive cash flow of $20 M in 2009
- $31 M received in Q4 for license option extension

4. Proven technology platform (PEGylation will extend the "shelve-life" of drugs ... there's a company in Japan, Yushi Seihin is well-known for this technology ... )

5. Diverse R&D pipline
- Multiple therapeutic areas including high-value opportunities in pain and oncology
- NKTR-118 is the first successful PEGylation of oral small molecule; significant oral bioavailability with a PEGylated drug and demostrated the platform can modulate drug penetration into the CNS
- NKTR-102 for Ovarian Cancer, Breast Cancer in Phase 2
- NKTR-105 in cancer (myelosuppression) in Phase 1

6. Multiple high-value partnerships in place for late-stage products
- Partner with AstraZeneca to commercialise both NKTR-118 and NKTR-119 programs which includes $125 M cash upfront to Nektar
- NKTR-188 for opioid-induced constipation ($235 M in development milestones, $375 M in sales milestones, double-digit royalities)
- NKTR-119 for pain relief without OIC ($75 M in development milestone, $310 M in sales milestones, double-digit royalities)

- A total of up to 1.5 B in milestones in addition to royalities ... ... (ok if they don't spend more to develop their technologies ... )

:arrow: No entry yet, will wait and monitor ...
[Finance disclaimer: The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought regarding investing of any stocks/ funds and/or whatsoever. The author has no vested interest in the mentioned stock at the time of writing.
helios
Permanent Loafer
 
Posts: 3608
Joined: Wed May 07, 2008 8:30 am

Re: Nektar Therapeutics (NKTR)

Postby winston » Wed Mar 07, 2018 8:48 pm

not vested

BIG GAINS IN REVOLUTIONARY TREATMENTS

Today's chart is more proof of our colleague Dave Eifrig's bullish call on health care stocks...

Dave's central idea is that the aging Baby Boomer generation will drive big gains in health care stocks. As the Boomers get older, they'll need more medicine, testing, and doctor's visits. Not only that, but they'll also live longer with the development of revolutionary drugs.

That's where Nektar Therapeutics (NKTR) comes in... This leading biopharmaceutical firm develops new drugs to treat illnesses like cancer, chronic pain, and auto-immune disease.

The company's shares soared in November after it reported positive trial data on NKTR-214 – one of its new experimental cancer drugs.

Then last month, Nektar signed a $3.6 billion deal with Bristol-Myers Squibb (BMY) to license NKTR-214. The announcement kicked off another big rally in NKTR shares...

As you can see below, shares have surged since November. They're up nearly 600% since this time last year... and just hit a new all-time high. Nektar has an exciting pipeline of new cancer treatments... And as it signs new deals, its shares will likely continue to thrive...

Source: Daily Wealth
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am


Return to L to R

Who is online

Users browsing this forum: No registered users and 5 guests